From: Metabolic syndrome and the risk of urothelial carcinoma of the bladder: a case-control study
Components | UCB Cases | Controls | OR (95 % CI)a | OR (95 % CI)b | ||
---|---|---|---|---|---|---|
n | (%) | n | (%) | |||
Diabetes mellitus | ||||||
No | 443 | (83.1) | 435 | (92.0) | Ref | Ref |
Yes | 90 | (16.9) | 38 | (8.0) | 2.22 (1.45-3.39) | 2.20 (1.42-3.38) |
Drug-treated hypertension | ||||||
No | 316 | (59.3) | 279 | (59.0) | Ref | Ref |
Yes | 217 | (40.7) | 194 | (41.0) | 0.99 (0.75-1.31) | 0.88 (0.66-1.17) |
Drug-treated hyperlipidaemia | ||||||
No | 442 | (82.9) | 399 | (84.4) | Ref | Ref |
Yes | 91 | (17.1) | 74 | (15.6) | 1.21 (0.84-1.73) | 1.16 (0.80-1.67) |
Abdominal obesityc | ||||||
No | 145 | (27.2) | 167 | (35.3) | Ref | Ref |
Yes | 388 | (72.8) | 306 | (64.7) | 1.65 (1.23-2.21) | 1.63 (1.22-2.19) |
Nr. of MetS components | ||||||
None | 83 | (15.6) | 85 | (18.0) | Ref | |
1 | 213 | (40.0) | 208 | (44.0) | 1.03 (0.70-1.51) | |
2 | 154 | (28.9) | 138 | (29.2) | 1.23 (0.81-1.85) | |
3 | 67 | (12.6) | 40 | (8.5) | 2.00 (1.17-3.41) | |
4 | 16 | (3.0) | 2 | (0.4) | 7.93 (1.71-36.79) | |
χ2 for trend; p-value | 11.45; P < 0.01 | |||||
Increment of 1 MetS component | 1.29 (1.11-1.49) | |||||
Indicators of MetSd | ||||||
No | 450 | (84.4) | 431 | (91.1) | Ref | |
Yes | 83 | (15.6) | 42 | (8.9) | 2.09 (1.38-3.19) | |
"Without diabetes" | 29 | (5.4) | 26 | (5.5) | 1.16 (0.65-2.07) | |
"With diabetes" | 54 | (10.1) | 16 | (3.4) | 3.63 (1.99-6.61) |